Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, and thank you for standing by. Welcome to the Arcutis Biotherapeutics, Inc. First Quarter twenty twenty six Earnings Conference Call. At this time, all participants are in listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Brian Shalkoff, Head of Investor Relations. Please go ahead. Thank you, Marvin. Good afternoon, everyone, and thank you for joining us today to review our first quarter twenty twenty six financial results and business update. Slides for today's call are available on the investors section of the Arcutis website. Joining me on the call today are Frank Watanabe, president and CEO of Arcutis Todd Edwards, chief commercial officer Patrick Burnett, Chief Medical Officer and Lotte Biotherapeutics, Chief Financial Officer. I'd like to remind everyone that we will be making forward looking statements during this call. These statements are subject to certain risks and uncertainties, and our actual results may differ. We encourage you to review all the company's filings with the Securities and Exchange Commission, including descriptions of our business and risk factors. With that, let me hand it over to Frank to begin today's call. Thanks, Brian, and good afternoon, everyone. As always, we appreciate you guys making the time to join us. I wanna start today's call with an overview of the latest developments at Arcutis and the progress we're making against our grow, expand, bu...